Cargando…

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center

BACKGROUND: According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luz, Jose Hugo Mendes, Luz, Paula M., Martin, Henrique S., Gouveia, Hugo R., Levigard, Raphal Braz, Nogueira, Felipe Diniz, Rodrigues, Bernardo Caetano, de Miranda, Tiago Nepomuceno, Mamede, Marcelo Henrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295188/ https://www.ncbi.nlm.nih.gov/pubmed/28166821 http://dx.doi.org/10.1186/s40644-017-0108-6

Ejemplares similares

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC
por: Kondo, Yasuteru, et al.
Publicado: (2022)

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
por: Zhu, Dedong, et al.
Publicado: (2019)

Neuroendocrine Tumor Treated with Arterial Chemoembolization Using DEB-TACE
por: Suzuki, Ko, et al.
Publicado: (2019)

Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
por: Li, Ningjie, et al.
Publicado: (2022)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMI(TM) Beads in HCC Patients: Preliminary Experience
por: Angileri, Salvatore Alessio, et al.
Publicado: (2023)

Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography
por: Tamura, Masashi, et al.
Publicado: (2021)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023)

Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Li, Baojian
Publicado: (2022)

Percutaneous solutions for biliary stent dysfunction: pictorial essay
por: Nunes, Thiago Franchi, et al.
Publicado: (2021)

Retracted: Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Healthcare Engineering, Journal of
Publicado: (2023)

Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study
por: Xiang, Hua, et al.
Publicado: (2019)

Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
por: Chai, Bin, et al.
Publicado: (2022)

Portal vein embolization with n-butyl-cyanoacrylate through an ipsilateral approach before major hepatectomy: single center analysis of 50 consecutive patients
por: Luz, José Hugo Mendes, et al.
Publicado: (2017)

Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
por: Ayyub, Javaria, et al.
Publicado: (2023)

The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE)
por: Fronda, Marco, et al.
Publicado: (2022)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE
por: Hu, Wenchao, et al.
Publicado: (2023)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
por: Pitton, Michael B., et al.
Publicado: (2014)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study
por: Yao, Qi, et al.
Publicado: (2017)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
por: Tipaldi, Marcello Andrea, et al.
Publicado: (2021)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Hepatic transarterial chemoembolization and retroperitoneal lymph node radiofrequency ablation in the multidisciplinary approach of an overt metastatic leiomyosarcoma
por: de Lima Araujo, Luiz Henrique, et al.
Publicado: (2013)

Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?
por: Somma, Francesco, et al.
Publicado: (2015)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upa7bphk471oti4o56knep2acg